Shaofeng Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaofeng Sun has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Guilan Yang
Department of Pulmonary and Critical Care Medicine General Hospital of Ningxia Medical University Yinchuan, Ningxia China
1 shared publication - Hong Zhang
Department of Pulmonary and Critical Care Medicine General Hospital of Ningxia Medical University Yinchuan, Ningxia China
1 shared publication - Hongyan Fu
Department of Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China
1 shared publication - Juan Chen
Ningxia Key Laboratory of Clinical and Pathogenic Microorganisms, Institute of Medical Science, General Hospital of Ningxia Medical University
1 shared publication - Shuhong Chi
Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China
1 shared publication - Weirong Ma
Department of Pulmonary and Critical Care Medicine General Hospital of Ningxia Medical University Yinchuan, Ningxia China
1 shared publication
Latest Publications
- Open Access
- 23 January 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (1) , e6840
Coexistence of anti‐MDA5 and anti‐PL‐7 in a patient with dermatomyositis: A case report
Coexisting anti‐MDA5 and anti‐PL‐7 antibodies are extremely rare. Anti‐MDA5 is associated with rapidly progressive interstitial lung disease (RP‐ILD), while anti‐PL‐7 is often associated with chronic or subacute ILD and better outcomes than RP‐ILD. We report a 41‐year‐old woman diagnosed with dermatomyositis (DM)‐associated ILD positive for anti‐MDA5 and anti‐PL‐7.
- 23 January 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (1) , e6840
Open AccessCoexistence of anti‐MDA5 and anti‐PL‐7 in a patient with dermatomyositis: A case report
Coexisting anti‐MDA5 and anti‐PL‐7 antibodies are extremely rare. Anti‐MDA5 is associated with rapidly progressive interstitial lung disease (RP‐ILD), while anti‐PL‐7 is often associated with chronic or subacute ILD and better outcomes than RP‐ILD. We report a 41‐year‐old woman diagnosed with dermatomyositis (DM)‐associated ILD positive for anti‐MDA5 and anti‐PL‐7.